SCHEMBL30775367

SCHEMBL30775367

O=C1NCc2c1cccc2N1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
MEN1 O00255 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CDK5 Q00535 2/20 0.49
DYRK1A Q13627 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
PIM1 P11309 1/20 0.49
CSNK1A1 P48729 1/20 0.49
ROCK1 Q13464 1/20 0.49
LRRK2 Q5S007 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
LTK P29376 1/20 0.43
MST1R Q04912 1/20 0.43
NSD2 O96028 2/20 0.43
LMNA P02545 1/20 0.43
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468497 0.85 PARP1 (0.51) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL2346037 0.83 CDK5 (0.50) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL30843943 0.83 CDK5 (0.50) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL30543333 0.81 CNR2 (0.52) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL2346359 0.78 DRD2 (0.46) CDK5DYRK1ACLK4PIM1CSNK1A1
SCHEMBL30775261 0.76 L3MBTL1 (0.52) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL30775209 0.75 CNR2 (0.58) MAPTBRD4ALDH1A1
SCHEMBL1239433 0.75 MEN1 (0.55) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL15487953 0.71 GRM5 (0.56) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL29698264 0.71 PARP1 (0.55) L3MBTL1MAPTNSD2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
WO-2025038747-A1 MODIFIED THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF RS ONCOLOGY, LLC (US) 2025-02-20 WO disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR L3MBTL1 4366/4885MEN1 1984/4885NPC1 89/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR L3MBTL1 4366/4885MEN1 1984/4885NPC1 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.